Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL17275151 | 1.00 | DNM1 (0.57) | — | |
| Bromide SCHEMBL9460989 | 1.00 | DNM1 (0.57) | — | |
| Bromide SCHEMBL22655241 | 1.00 | DNM1 (0.57) | — | |
| Bromide SCHEMBL1114924 | 1.00 | — | — | |
| Bromide SCHEMBL3006785 | 1.00 | DNM1 (0.57) | — | |
| SCHEMBL7516444 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL1695732 | 0.96 | — | — | |
| SCHEMBL19037263 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL345699 | 0.96 | — | — | |
| SCHEMBL4373470 | 0.96 | DNM1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304898-B2 | Quinolyl-containing compound and pharmaceutical composition, and use thereof | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| CN-119039164-B | Ionizable lipid compounds, lipid nanoparticles comprising same, pharmaceutical compositions, pharmaceutical formulations and uses thereof | 国药中生生物技术研究院有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119039164-A | Ionizable lipid compounds, lipid nanoparticles comprising same, pharmaceutical compositions, pharmaceutical formulations and uses thereof | 国药中生生物技术研究院有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118420604-A | EZH2 protein degradation agent modified by norbornene as hydrophobic group, and preparation method and application thereof | 中国药科大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-116239893-B | Quaternary ammonium salt modified cyanine fluorescent dye and its synthesis and application | 大连理工大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-113924288-B | Quinolinyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| CN-116239893-A | Quaternary ammonium salt modified cyanine fluorescent dye and its synthesis and application | 大连理工大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3950677-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939342-A | Triphenylphosphonium-linked salicylamine derivatives | MTI生物技术公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113924288-A | Quinolyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3914359-A1 | TRIPHENYLPHOSPHONIUM-TETHERED SALICYLAMINE DERIVATIVES | MTI Biotech, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154731-A1 | TRIPHENYLPHOSPHONIUM-TETHERED SALICYLAMINE DERIVATIVES | MTI BIOTECH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-0865429-A1 | AZETIDINONE COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021676-A1 | AZETIDINONE COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | disclosed |